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Background For several years, acute coronary syndromes
have been perceived as causing the most hospital admis-
sions, and even hospital mortality. The syndrome of unsta-
ble angina frequently progresses to acute myocardial
infarction but its pathogenesis is poorly understood, and
prognosis determination is still problematic. We tested the
hypothesis that measurement of the C-reactive protein in
patients admitted for chest pain could be a marker for acute
coronary syndromes.
Methods and Results We studied 110 patients admitted
with suspected ischaemic heart disease, but without
elevated serum creatine-kinase levels at the time of hospital
admission. Patients were subsequently divided into two
groups based on their final diagnosis: group 1 comprised
patients with unstable angina; group 2 patients with acute
myocardial infarction. We measured the C-reactive protein
at the time of hospital admission. The concentration of
C-reactive protein was elevated in 59% of the patients with
a final diagnosis of acute myocardial infarction, and in 5%
of the patients with a final diagnosis of unstable angina,
Conclusion This study indicates that C-reactive protein
levels measured at the time of admission in patients with
suspected ischaemic heart disease could be a marker for
acute coronary syndromes, and helpful in identifying
patients at high risk for acute myocardial infarction.
Measurement of C-reactive protein may have practical
clinical significance in the management of patients hospital-
ized for suspected acute coronary syndromes.
(Eur Heart J 1997; 18: 1897-1902)
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Introduction
The clinical manifestation of acute coronary syndromes,
which include both acute myocardial infarction and
unstable angina, may largely depend on the presence
and severity of functional factors that transiently and
acutely interfere with coronary blood flow, together
with an extremely variable degree of coronary athero-
sclerosis'11. In the past, several studies have described an
increase in C-reactive protein after myocardial infarc-
tion, which may reflect an important inflammatory
component in this clinical situation'2"41. The syndrome
of unstable angina occurs most commonly in the setting
of atherosclerotic coronary artery disease and frequently
progresses to acute myocardial infarction. Coronary
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thrombosis and vasospasm are known to be implicated
in the pathogenesis of myocardial infarction15-61, but the
underlying causes of unstable angina are not clear.
Although the cell biology of atherosclerosis is not
completely defined, inflammation may play a part in
unstable angina, as suggested by histological studies of
coronary plaques'71, the release of thromboxanes and
leukotrienes'8'9', the increased expression of leukocyte
receptors in the presence of activated circulating leuko-
cytes that may include coronary vasoconstriction,
favour thrombotic processes, and activate platelets1'01.
Currently, there is a reduction in the time
between the onset of chest pain and hospital admis-
sion'11!. As more patients with acute ischaemic heart
disease will be hospitalized in the future, predicting the
prognosis of these patients very early and managing
them accordingly will be crucial. Recently, two studies
reported on the possible prognostic value of circulating
active-phase C-reactive protein, which may reflect
the inflammatory pathogenesis in patients suffering
unstable angina'12'131. To characterize the presence of
'active' atherosclerotic lesions in patients admitted with
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suspected acute ischaemic heart disease, we measured
the value of C-reactive protein at the time of hospital
admission and compared it with the final diagnosis of
these patients.
Methods
Patients
The study population comprised 110 of 201 consecutive
patients admitted to the emergency centre of the Geneva
Hospital with chest pain between January and June
1994, and in whom myocardial infarction was suspected
according to the clinical and electrocardiographic cri-
teria of the Imminent Myocardial Infarction Rotterdam
Study'141. There were 90 men and 20 women, with a
mean ( ± SD) age of 65 ± 11 years. The criteria for
enrollment were the following: chest pain at rest, with at
least two episodes in the previous 48 h, or one episode
lasting more than 20 min; ST-segment changes on ECG
diagnostic of myocardial ischaemia during anginal at-
tacks; no elevation of serum creatine kinase and creatine
kinase-MB levels at the time of hospital admission. The
criteria for exclusion were an interval of more than 24 h
since the last ischaemic episode before hospitalization
(47 patients), intercurrent inflammatory or neoplastic
conditions likely to be associated with an acute-phase
response (29 patients), acute myocardial infarction
within the previous month (eight patients), valvular
heart disease (four patients), and chronic dissecting
aortic aneurysm (three patients). All patients were
studied prospectively without knowledge of C-reactive
protein serum levels. Ninety-eight patients (89%) stayed
in the intensive care unit for 2-4 ± 2-4 days after admis-
sion. All patients received various combinations of
intravenous or oral nitrates, beta-blockers, aspirin,
heparin and calcium antagonists. Nineteen patients
(17%) were treated with thrombolysis (rTPA) started
in the emergency room. Coronary angiography was
performed within 2-5 ± 2-2 days of admission in 103
patients (94%), 63 patients (57%) underwent percu-
taneous transluminal coronary angioplasty, and 24
(22%) coronary artery bypass grafting.
These 110 patients were divided into two groups
based on their final diagnosis: Group 1 comprised 61
patients with a final diagnosis of unstable angina (51
men and 10 women; with a mean (± SD) age of 65 ± 11
years), and Group 2, 49 patients with a final diagnosis of
acute myocardial infarction (39 men and 10 women;
with a mean ( ± SD) age of 66 ± 12 years). The diagnosis
of acute myocardial infarction was made by a physician
independent of the study, according to the electrocardio-
graphic and enzymatic criteria of the World Health
Organization for acute myocardial infarction (maximal
creatine kinase activity, >270 U . I " 1 in men and
> 1 7 0 U . l ~ ' in women, or >8% of creatine kinase-
MB1151, on the basis of their evolution during the 24 h
following the admission. These patients developed their
acute myocardial infarction 12 ± 10 h after admission.
Among them, eight patients (16%) had persistent ST
elevation on admission.
Study protocol
For all patients, venous blood samples were obtained at
the time of hospital admission, every 4 h thereafter
during the first day, and daily for the next 3 days. Total
creatine kinase and creatine kinase-MB levels were
determined routinely when the blood samples were
obtained. The first blood samples obtained at the time of
hospital admission were stored at - 20 °C and analysed
for C-reactive protein and cardiac troponin T at the
end of the study. All decisions regarding the care of
the patients were made by the physicians in charge,
independent of these measurements.
Plasma protein assays
C-reactive protein was assayed by a fluorescence polar-
ization automated monoclonal-antibody, solid-phase,
sandwich-type enzyme immunoassay (TDxFLx, Abbott
Laboratories, North Chicago, IL, U.S.A.)116"181. The
range of values detected by the assay is 000 to 26 mg per
decilitre, With this method, the median normal value
for C-reactive protein, <0-5mg.dl~ ' in 95%, and
< 10 mg . dl ~ ' in 98% of normal healthy volunteers'19',
conforms with a previous report using different meth-
ods1201. Cardiac troponin T was measured by an enzyme
immunoassay (Boehringer Mannheim, Mannheim,
Germany)'2'1. Values >0-20ug.l~' were considered
positive for cardiac troponin T in this study. The activity
of creatine kinase was measured colorimetrically at
37 °C (NAC, Merck, Darmstadt, Germany) by the stan-
dard method of the European Committee for Clinical
and Laboratory Standard1221. Creatine kinase isoenzyme
MB activity was assessed by an immunoinhibition assay
(NAC, Merck, Damstadt, Germany). All three protein
immunoassays were performed by technicians who were
unaware of the clinical data.
Statistical analysis
Data are presented as the mean ± standard deviation, or
counts. A Mann-Whitney test was used to compare
variables measured from the patients1231. P values less
than 005 (two-tailed) were considered to indicate
statistical significance.
Results
The characteristics of the two groups of patients are
listed in Table 1. There were no clinical differences
between the two groups, which differed only in their
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Table 1 Levels of C-reactive protein and population characteristics
Variables
Mean C-reactive protein ( ± SD) (mg . dl ~ ' )
level on admission
M in—max
Median
Age (m ± SD) (years)
Sex (M/F)
Interval between onset of last (h)
episode of pain and admission (m ± SD)
BP systolic (m ± SD)
BP diastolic (m ± SD)
Heart rate (m ± SD)
NYHA class on admission
1
II
III
IV
Myocardial infarction
Q wave/non-Q wave
Anterior
Inferior
Apical
Lateral
Posterior
Risk factors
Family history
Hypercholesterolaemia
Diabetes
Hypertension
Smoking
Medication used
Oral nitrates
Intravenous nitrates
Beta-blockers
Calcium blockers
Aspirin
Heparin
Thrombolytic agents
Cardiac history
Myocardial infarction
(> 1 month before admission)
Angina
CABG
PTCA
Group 1
(n = 61)
0-50 ± 0-27
000-1 06
0-55
65 ±11
51/10
5-9 ±3-2
147 ±28 (mmHg)
86±16(mmHg)
80 ± 16 (per min)
48
12
1
0
0
27
34
11
32
32
6
56
6
1
42
53
1
22
23
5
15
Group 2
(n=49)
1-70 ±2-21
0-00-11 01
100
66 ±12
39/10
61 ±4-2
134 ±26 (mmHg)
81 ± 17 (mmHg)
81 ± 19 (per min)
32
14
3
0
49
20/29
23
18
13
12
4
23
22
5
17
31
6
44
3
0
39
43
18
13
18
2
4
P value
<0001
<0001
NS
NS
NS
001
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
<0001
NS
NS
NS
004
NS=non-significant
CABG=coronary artery bypass grafting
PTCA = percutaneous transluminal coronary angioplasty.
final diagnosis (group 1: unstable angina; group 2: acute
myocardial infarction). Age, sex, cardiovascular risk
factors, and baseline therapy were similar. There were
no significant differences between the two groups in the
number of stenotic coronary vessels, or in the pattern of
coronary artery disease demonstrated by angiography.
Thirty-eight patients (62%) in group 1 and 25 (51%) in
group 2 underwent percutaneous transluminal coronary
angioplasty; 12 patients (20%) in group 1 and 12 (24%)
in group 2 underwent coronary artery bypass grafting;
eight patients died in hospital, all in group 2 (/>=0-004).
At the time of admission, all patients had normal
creatine kinase and creatine kinase-MB serum levels.
Patients with ultimate confirmed diagnosis
of unstable angina (Group 1)
The concentration of C-reactive protein at the time of
hospitalization was >0-9 mg . dl~ ' in only three (5%) of
the 61 patients (1-3; 1-3 and l -4mg.dl~ ' , respectively),
with a final diagnosis of unstable angina (Fig. 1);
the mean value of C-reactive protein was 0-50 ±
0-27mg.dl~' . The mean maximal concentrations of
total creatine kinase ( 1 2 4 ± 5 9 I U . r ' [range 38-263;
reference range, <170IU for women and <270 IU for
men]), and creatine kinase-MB (6-1 ± 0-9% [range,
0-7-6; reference range, <8% of the total creatine kinase
Eur Heart J, Vol. 18, December 1997
1900 F. Much et al.
12
10
o
Max 0
-pP95%
Median
Min
11 Mean P75%
P25%
P5%
Group 1 Group 2
Figure 1 Elevation of C-reactive protein in patients admitted with suspected acute
coronary syndromes. Group 1: ultimated confirmed diagnosis of unstable angina;
Group 2: ultimated confirmed diagnosis of acute myocardial infarction. (/}<0-001
between groups).
if > 170 IU . 1 ' for women and 270IU for men) were
normal in all patient samples. The mean concentrations
of cardiac troponin T at the time of hospital admission
(0-037 ± 007 ug . r ' [range, 0-00-0-37; reference range,
0-00-0-2 ug . 1 ~']) were >0-2ug. l~ ' in only three
patients (5%). There were no clinical or angiographic
differences between patients with levels of C-reactive
protein >0-9 mg . dl ~ ' and <0-9 mg . dl ~ '.
Patients with ultimate confirmed diagnosis
of acute myocardial infarction (Group 2)
The concentration of C-reactive protein at the time of
hospital admission was ^ O ^ m g . d l " 1 in 29 (59%) of
the 41 patients with a final diagnosis of acute myocardial
infarction, (F<0001 in comparison with Group 1;
Fig. 1). The mean value of C-reactive protein was
1 -70± 2-21 mg . d l" 1 . The mean maximal concen-
trations of total creatine kinase were 2150 ±
2507 I U . l " 1 [range, 218-8707; reference range,
> 170 IU for women and >270 for men], and of creatine
kinase-MB 14-9 ± 8-6 IU . 1~' [range, 8-6-51; reference
range, >8% of the total creatine kinase if >170 IU . 1" '
for women and >270 for men]. The elevation of creatine
kinase and creatine kinase-MB appears 5-2 ± 2-7 h after
onset of symptoms. The mean concentrations of cardiac
troponin T (0-20±0-49 ug . 1 ~' [range, 000-2-41;
reference range, 0-0-2 ug. 1 ~']) were >0-2 jig . 1 ~ ' in
seven patients (14%). The elevation of cardiac troponin
T appears 4-9 ± 2-8 h after onset of symptoms. There
was no difference in C-reactive protein level between the
patients with or without a Q wave acute myocardial
infarction. Among the 29 patients with elevated
C-reactive protein and acute myocardial infarction, 12
(41%) had severe ST elevation (Pardee wave) suggestive
of acute ischaemia at the time of hospitalization. Apart
from that, we found no other obvious independent
evidence of acute myocardial infarction on admission.
There were no clinical or angiographic differences
between patients with levels of C-reactive protein
>0-9mg.dl~ ' and those with <0-9mg.dl~ ' . The
detailed C-reactive protein levels of both groups are
shown in Table 2.
Discussion
The syndrome of unstable angina nearly always occurs
in the setting of atherosclerotic coronary artery disease.
Increasingly, it is apparent that functional attributes
rather than size alone determines the propensity of
atherosclerotic plaque to provoke acute coronary events.
Inflammation may contribute to weakening of the
atherosclerotic plaque and could play a crucial role in
the rupture of the fibrous cap, with subsequent exposure
of the lipid-core to circulating blood components, result-
ing in coronary thrombosis. Previous studies have
registered elevated values for acute-phase proteins in
patients with unstable angina and acute myocardial
Eur Heart J, Vol. 18, December 1997
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Table
Group
Group
2
1
2
C-reactive protein (mg.
Max
106
1101
Min Mean
000 0-50
000 1-70
dl~') in
Median
0-55
100
acute coronary
P 99%
106
1101
P 1%
000
000
syndromes
P 5 %
000
000
P 95%
0-88
1101
SD
0-27
2-21
Group 1= Patients with ultimate confirmed diagnosis of unstable angina.
Group 2 = Patients with ultimate confirmed diagnosis of acute myocardial infarction.
(P=percentile, SD = standard deviation).
infarction'23'. In 1994, Luizzo and colleagues reported
the prognostic importance of C-reactive protein for
patients with unstable angina'121, and more recently,
Thompson and colleagues demonstrated that haemo-
static factors and C-reactive protein are predictive
markers of acute coronary syndromes'131. We tested the
hypothesis that inflammation within the coronary ves-
sels may reflect the severity of lesions implicated in
plaque rupture. The results of our study confirm the
observation that, among patients with acute ischaemic
heart disease and no biological marker of myocardial
necrosis, the plasma concentration of C-reactive protein
at the time of admission was significantly higher in
patients in whom an acute myocardial infarction
was ultimately diagnosed, which makes it an impor-
tant prognostic marker and a useful tool for clinical
management.
Compared to previous studies124"261, the percent-
age of patient with elevated cardiac troponin T level and
unstable angina in our subjects was low. One expla-
nation for this finding is the small interval between onset
of symptoms and hospital admission in our group of
patients (5-6 h). Indeed, the level of cardiac enzymes
measured during acute coronary events depends directly
on the duration of symptoms. It is unlikely that these
patients with unstable angina had less acute disease,
since their coronary angiographic findings were similar
to the patients with acute infarction. Previous history of
percutaneous transluminal coronary angioplasty was
higher in patients with unstable angina, but symptoms
related to restenosis occurred only in two of 15 (13%),
which was similar in the group of patients with acute
myocardial infarction (15%). Interestingly, the three
patients with elevated cardiac troponin T in this un-
stable angina group corresponded to those with a
C-reactive protein >0-9mg.d l~ ' described above.
Finally, the high percentage of patients (41%) with acute
myocardial infarction and normal C-reactive protein
levels could be due, in out study, to the small interval
between onset of symptoms and hospital admission
(61 h).
The acute phase of C-reactive protein is a non-
specific phenomenon reflecting cytokine-mediated
hepatic production triggered by most forms of inflam-
mation, infection and tissue injury. Our patients were
carefully selected to eliminate intercurrent disorders
likely to be associated with an acute-phase response,
and similar attention to intercurrent processes will be
essential for the practical application of our findings.
The elevation of C-reactive protein in acute
coronary syndromes is probably related to 'coronary
arteritis', and inflammation may then contribute to both
vasospasm and thrombosis. Activated vascular wall
cells, such as smooth muscle cells, endothelial cells,
macrophages, and T lymphocytes, may play a central
role because they produce molecules such as interleukin,
adhesion molecules, growth factors, procoagulant
activity, that alter both vascular reactivity and
thrombogenicity'271. Elevation of C-reactive protein may
therefore reflect the central role of inflammation in the
pathophysiology of 'active' coronary artery disease. The
beneficial effects of aspirin in unstable angina'28"301 could
reflect decreased inflammation in addition to decreased
platelet aggregation. In agreement with this hypothesis,
Ridker and colleagues demonstrated recently that in
apparently healthy men, a high baseline plasma
C-reactive protein level predicts the risk of future myo-
cardial infarction (P<0001), and that the use of aspirin
was associated with significant reduction in the risk of
acute myocardial infarction (/><002)'3'1.
Early prognostic assessment of myocardial in-
farction is a key to optimal therapy and management of
patients with this common disease, but entirely depends
on the availability of rapid and specific diagnostic tests.
Thus, the predictive correlation between C-reactive
protein levels at the time of admission and the clinical
outcomes may have practical clinical importance in the
management of patients hospitalized for acute coronary
syndromes, and possible cost-saving potential. In actual
clinical practice, a C-reactive protein result can be
obtained within 60 min. Our results led us to conclude
that, in patients with suspected myocardial infarction,
the measurement of C-reactive protein at the time of
admission could lead to an improvement in the manage-
ment of myocardial ischaemia, increasing prognostic
security, and decreasing delay to appropriate triage and
treatment. Large prospective studies are necessary to
confirm these findings.
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